Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mps-BAY2b |
Synonyms | |
Therapy Description |
Mps-BAY2b, is an imidazopyrazine that inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23933817, PMID: 28539250). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mps-BAY2b | MPS1 Inhibitor 27 | Mps-BAY2b, is an imidazopyrazine that inhibits TTK (MPS1) to derail the spindle assembly checkpoint and induce cell cycle arrest (PMID: 23933817, PMID: 28539250). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 S45del | colon carcinoma | predicted - sensitive | Mps-BAY2b | Preclinical - Cell culture | Actionable | In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colon carcinoma cell line harboring CTNNB1 S45del, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540). | 28751540 |
CTNNB1 S45F | colorectal adenocarcinoma | predicted - sensitive | Mps-BAY2b | Preclinical - Cell culture | Actionable | In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S45F, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540). | 28751540 |
CTNNB1 T41A | lung cancer | predicted - sensitive | Mps-BAY2b | Preclinical - Cell culture | Actionable | In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a lung cancer cell line harboring CTNNB1 T41A, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540). | 28751540 |
CTNNB1 S33Y | colorectal adenocarcinoma | predicted - sensitive | Mps-BAY2b | Preclinical - Cell culture | Actionable | In a preclinical study, cell lines harboring CTNNB1 hotspot mutations, including a colorectal adenocarcinoma cell line harboring CTNNB1 S33Y, demonstrated increased sensitivity to Mps-BAY2b compared to cell lines with wild-type CTNNB1 in culture (PMID: 28751540). | 28751540 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|